Urology Austin,

Austin, Texas 78759

11 studies enrolling now · 29 studies all time

What they study most

BPH With Symptomatic Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer, Carcinoma of the Prostate, Diagnostic Imaging, Elevated PSA, FGFR Gene Alterations, FGFR Gene Amplification, FGFR3 Gene Alteration, FGFR3 Gene Fusions, FGFR3 Gene Mutation

Studies at this site

• LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve — Recruiting now
• Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer — Recruiting now
• A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer — Recruiting now
• Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer — Recruiting now
• A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer — Recruiting now
• PSMA PET Combined With MRI for the Detection of PCa — Recruiting now
• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer — Recruiting now
• Post-Approval Study of the Neuspera Sacral Neuromodulation System — Recruiting now
• Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial — Recruiting now
• WATER IV PCa (AS Sub-study) — Starting soon
• Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy — Running, not enrolling
• ProVee Urethral Expander System IDE Study (ProVIDE) — Running, not enrolling
• A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC — Starting soon
• A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX — Completed
• ProVIDE II Bridging Study — Running, not enrolling
• A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) — Running, not enrolling
• A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer — Running, not enrolling
• Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer — Running, not enrolling
• Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence — Starting soon
• WATER IV Prostate Cancer — Running, not enrolling
• A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases — Completed
• Comparison of Laser Lithotripsy With and Without Steerable Ureteroscopic Renal Evacuation (SURE) — Completed
• Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI) — Running, not enrolling
• Comparing UroLift Experience Against Rezūm — Running, not enrolling
• Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer — Running, not enrolling
• Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer — Stopped early
• PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients — Completed